Eli Lilly (LLY) Stock Surges on Back-to-Back Analyst Price Target Increases

Key Highlights

Table of Contents

JPMorgan increased its Eli Lilly price objective to $1,400 from $1,300 while maintaining an Overweight stance
RBC Capital pushed its forecast higher to $1,500 from $1,250, retaining an Outperform designation
The revisions reflect robust commercial traction for the obesity treatments Mounjaro and Zepbound
A new Medicare GLP-1 Bridge initiative beginning July 1 offers Zepbound for approximately $50 monthly
Shares are hovering around $1,235, climbing about 14% this year and approaching the 52-week peak of $1,249.45

On Tuesday, JPMorgan’s Chris Schott elevated his Eli Lilly price objective to $1,400 from $1,300, reaffirming his Overweight recommendation. This revised forecast exceeds the Street’s consensus estimate of roughly $1,305.

Eli Lilly and Company, LLY

Coinciding with the analyst upgrade, LLY shares marked a new 52-week high during Tuesday’s session. Schott identified Lilly as his preferred selection within the healthcare sector.

RBC Capital followed suit the same day, elevating its price objective to $1,500 from $1,250 while keeping its Outperform rating intact. The firm noted its internal revenue models track approximately 1% above consensus, with Zepbound and Mounjaro performance exceeding forecasts by 5%-6%.

Eli Lilly shares currently trade near $1,235, reflecting a roughly 7.5% gain over the past thirty days and approximately 14% appreciation year-to-date. The stock’s 52-week bottom stands at $623.78.

Schott’s analysis anticipates Q2 revenue reaching approximately $20.7 billion for Lilly, exceeding consensus estimates by roughly $300 million. He identified two primary catalysts: Mounjaro’s geographical expansion internationally and consistent U.S. commercial momentum for Zepbound.

During Q1 2026, the pharmaceutical giant reported revenue of $19.8 billion, marking a 55.5% year-over-year surge. Mounjaro and Zepbound collectively generated approximately $12.8 billion in worldwide sales during that period. Domestic revenue climbed 43% to $12.1 billion, powered by a 49% volume increase.

Following these results, Lilly elevated its full-year 2026 revenue outlook to a range of $82 billion to $85 billion.

Medicare Initiative Creates Additional Revenue Catalyst

Beginning July 1, Medicare’s freshly launched GLP-1 Bridge initiative extended access to Zepbound and oral medication Foundayo for qualified enrollees at costs as low as $50 monthly. With approximately 20 million Medicare beneficiaries potentially eligible, certain analysts believe even the $1,400 projection might underestimate future performance.

Expanded affordability generally translates to increased prescription volumes, directly impacting the revenue metrics financial analysts monitor.

Demand expansion has successfully counterbalanced the reduced pricing Lilly implemented in domestic markets, aligning with management’s previous investor guidance.

Development Pipeline Strengthens Investment Thesis

Beyond established blockbusters, Schott emphasized Lilly’s development portfolio as an additional confidence driver. Notable candidates include orforglipron, the oral GLP-1 currently marketed as Foundayo, along with retatrutide, a triple-agonist compound advancing through clinical trials. Schott estimates the total addressable market for these therapeutic agents exceeds $200 billion.

Rival setbacks have additionally benefited Lilly’s competitive position. Disappointing clinical data from smaller pharmaceutical companies have solidified Lilly’s market standing, strengthening what analysts describe as a substantial competitive advantage.

Lilly’s market capitalization currently approaches $1.16 trillion, with its price-to-earnings multiple hovering around 44.

The upcoming critical milestone arrives August 5, when the company releases second-quarter financial results. RBC highlighted strong prescription volume growth domestically and abroad, while anticipating pricing pressure in the low-to-mid-teen percentage range.

Schott views Q2 as potentially exceeding expectations, though shares trading near historical peaks establish elevated performance benchmarks on both sides.

✨ Limited Time Offer